Study guide

9.4 Drug Recalls (Class I, II, III) & Market Withdrawals

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

9.4 Drug Recalls (Class I, II, III) & Market Withdrawals

Key Takeaways Explain This Topic AI

Class I Recalls involve a reasonable probability of severe health consequences or death; recall actions must extend down to the patient/consumer level.

Class II Recalls involve temporary or medically reversible adverse health consequences; recall actions typically extend to the retail/pharmacy level.

Class III Recalls involve products unlikely to cause adverse health consequences; actions target wholesale/distributor levels for technical defects.

Drug recalls are voluntary actions undertaken by manufacturers; the FDA typically requests recalls but can initiate court-ordered seizure if a firm refuses.

A Market Withdrawal applies to products with minor quality defects that do not violate the FD&C Act, or products removed purely for commercial reasons.

Last updated: July 2026

9.4 Drug Recalls (Class I, II, III) & Market Withdrawals

MPJE Core Concept: Drug recalls represent critical risk-mitigation measures designed to remove defective, adulterated, or misbranded pharmaceuticals from commercial channels. Candidates must master the three FDA recall classifications (Class I, II, and III), understand the legal distinction between voluntary recalls and market withdrawals, and know exact pharmacy operational procedures for quarantining recalled stock and notifying affected patients.

1. Legal Foundations & FDA Statutory Authority

Voluntary Nature of Drug Recalls: Under the FD&C Act, most human drug recalls are voluntary actions initiated by the manufacturer or distributor to fulfill their legal responsibility to protect public health.

FDA Role & Authority:

The FDA typically requests or strongly urges a manufacturer to initiate a recall after discovering violative products during inspections or adverse event monitoring.

Mandatory Recall Authority: The FDA possesses explicit statutory authority to mandate recalls for medical devices, biological products, human tissue products, controlled substances (under the SUPPORT Act), and infant formula. However, for standard human prescription drugs, if a manufacturer refuses a voluntary recall request, the FDA enforces compliance by securing court orders for product seizure (21 U.S.C. § 334) or federal court injunctions prohibiting distribution.

2. FDA Drug Recall Classifications (21 CFR Part 7)

The FDA categorizes recalls into three distinct risk tiers based on the severity of potential health hazards to the public:

Class I Recall (Highest Risk / Severe Hazard)

Statutory Definition: A situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death .

Clinical Examples:

Label mix-up on a potent medication (e.g., 25 mg warfarin tablets labeled as 2.5 mg tablets).

Microbes/pathogens found in sterile injectable solutions or ophthalmic preparations.

Incorrect active ingredient or lethal chemical contaminant in a pediatric suspension.

Depth of Recall Action: Must extend down to the consumer / patient level . Wholesalers, pharmacies, prescribers, and patients who received the recalled product must be notified immediately to retrieve and isolate the medication.

Class II Recall (Moderate Risk / Temporary Hazard)

Statutory Definition: A situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences , or where the probability of serious adverse health consequences is remote.

Clinical Examples:

Sub-potent drug product that is not life-threatening (e.g., 10% loss of potency in a broad-spectrum antibiotic).

Microscopic foreign particles in an oral solid dosage form.

Container closure defect leading to minor moisture ingress and tablet degradation.

Depth of Recall Action: Typically extends to the retail / pharmacy level (pharmacies, hospitals, clinics, and wholesale distributors).

Class III Recall (Lowest Risk / Technical Defect)

Statutory Definition: A situation in which the use of or exposure to a violative product is not likely to cause adverse health consequences .

Clinical Examples:

Minor labeling error not affecting dosage or safety (e.g., misspelled non-critical word in package insert).

Omission of expiration date or lot number on an outer carton (where it is correctly printed on the inner bottle).

Minor container color variation or non-compliance with commercial formatting rules.

Depth of Recall Action: Typically restricted to the wholesale / distributor level .

3. Market Withdrawals vs. Medical Device Safety Alerts

Candidates must distinguish FDA-classified recalls from related regulatory actions under 21 CFR § 7.3:

Market Withdrawal

Definition: Occurs when a product has a minor defect or quality issue that does not violate the laws enforced by the FDA (i.e., does not rise to the level of adulteration or misbranding), or when a firm removes a product from the market due to commercial or economic reasons (e.g., low sales, product line discontinuation).

Key Distinction: A market withdrawal involves no statutory law violation. If a firm withdraws a product because of a minor cosmetic flaw or normal product improvement, it is categorized as a market withdrawal.

Medical Device Safety Alert

Definition: Issued for medical devices that present an unreasonable risk of substantial harm, where the situation may be resolved through device adjustment, repair, or operator re-training rather than physical removal from the market.

4. Pharmacy Operational Protocols & Pharmacist Responsibilities

When a recall notice is issued by the FDA or a drug manufacturer, pharmacy staff must follow a strict, standardized operational protocol: [Receive Recall Notice] ➔ [Identify Product & Lot Numbers] ➔ [Quarantine Stock in Locked Area] ➔ [Review Dispensing Software Logs] ➔ [Notify Affected Patients (Class I)] ➔ [Return Stock via Reverse Distributor]

Step-by-Step Operational Workflow

Notice Review: Immediately inspect the recall notice to identify the exact brand/generic name, dosage form, strength, package size, NDC, and specific lot numbers involved.

Inventory Inspection & Quarantine:

Search all pharmacy storage locations: active dispensing shelves, automated counting cells, emergency kits, night cabinets, and refrigerator/freezer units.

Immediately pull all affected lot numbers from inventory.

Place recalled stock in a designated, segregated, and clearly marked "Quarantine — DO NOT DISPENSE" area (preferably locked) to prevent accidental dispensing.

Patient Identification & Notification (Mandatory for Class I):

For Class I recalls, run prescription dispensing software reports to identify every patient who was dispensed medication from the recalled lot numbers.

Contact patients immediately by phone and via urgent written notice to inform them of the recall, instruct them to discontinue taking the recalled lot, and arrange for medication replacement.

Coordinate with prescribers to obtain replacement orders if an alternative drug entity is required.

Stock Return & Documentation:

Return recalled inventory to the manufacturer, wholesaler, or registered reverse distributor as instructed in the recall notice.

Maintain detailed records of all recall actions—including lot numbers pulled, quantities quarantined, destruction/return manifests, and patient notification logs—for a minimum of 2 years (or longer if mandated by state law).

Legal Liability for Non-Compliance

Dispensing a recalled medication after receiving notice constitutes strict civil and criminal liability under the FD&C Act. Dispensing a Class I recalled drug renders the product adulterated and/or misbranded , exposing the pharmacy and dispensing pharmacist to FDA enforcement actions, state board disciplinary proceedings, and civil malpractice lawsuits.

Loading diagram... FDA Recall Risk Classification Matrix